Apollo Hospitals Enterprise Limited (APOLLOHOSP) — Corporate Action | 30 May 2025(2 announcements)

Apollo Hospitals Enterprise Limited reported consolidated revenue of ₹21,794 crores for FY2025, up 14% YoY, with PAT at ₹1,446 crores (61% YoY growth) and EBITDA at ₹3,022 crores (26% YoY growth). The board declared a final dividend of ₹10 per share (total ₹19 per share) and set a record date of August 19, 2025, with the AGM scheduled for August 29, 2025. Credit ratings were reaffirmed by CRISIL and India Ratings. The company plans to add over 4,300 beds across India in 3-4 years with a capital outlay exceeding Rs. 8,000 crores, funded through internal accruals.

{ "summary": "Apollo Hospitals reported consolidated PAT of ₹4,145 million for Q1 FY25, up 61% YoY, driven by strong revenue growth to ₹55,922 million and robust healthcare services performance. The company declared a final dividend of ₹10 per share (200% of face value) pending AGM approval on August 29, 2025, with record date set for August 19, 2025. It reappointed key leadership including Som Mittal as Independent Director and retained Preetha, Suneeta, and Sangita Reddy. The audit confirmed unmodified opinions on financials, with CRISIL reaffirming AA+/Stable ratings. Expansion plans include adding 4,300+ beds across India by 2028 with ₹8,000 crores capital outlay, funded internally.", "extractedFields": { "keyEvent": "Apollo Hospitals declared a final dividend of ₹10 per share pending AGM approval on August 29, 2025.", "whatChanged": "61% YoY PAT growth to ₹4,145 million; revenue rose to ₹55,922 million; CRISIL reaffirmed AA+/Stable ratings; 4,300+ new beds planned by 2028.", "forwardGuidance": "August 29, 2025 AGM to approve final dividend; expansion to add 4,300+ beds by 2028.", "investorTakeaway": "Strong PAT growth and dividend declaration signal financial health, while expansion plans position long-term growth.", "dividend": { "final": { "amountPerShare": 10, "faceValue": 5, "percentageOfFaceValue": 200, "recordDate": "2025-08-19", "paymentDeadline": "2025-09-10" }, "interim": { "amountPerShare": 9, "recordDate": "2025-02-15", "paymentDate": "2025-02-28" } }, "creditRatings": { "longTerm": 2, "shortTerm": 1, "affirmingAgency": "CRISIL Ratings Limited" }, "cashFlow": { "operatingCashGenerated": 21169, "investingCashFlow": -10457, "financingCashFlow": -7391, "netCashChange": -429, "cashAtBeginning": 2761, "cashAtEnd": 2332 }, "auditOpinions": { "annualFinancials": "unmodified", "quarterlyReview": "limited review, no modifications" }, "regulatoryCompliance": "compliant with SEBI LODR Regulation 33", "totalAssets": { "2025": 206574, "2024": 167531 }, "totalEquity": { "2025": 86529, "2024": 73205 }, "totalLiabilities": { "2025": 120045, "2024": 94326 }, "revenueThreeMonths": 55922, "profitBeforeTax": 5155, "netProfit": 4145, "epsBasic": 27.10, "epsDiluted": 27.10, "segmentRevenue": { "healthcareServices": 10000, "retailHealthAndDiagnostics": 5000, "digitalHealthAndPharmacyDistribution": 2000 }, "dividendDeclarations": [ { "type": "final", "amountPerShare": 10, "recordDate": "19th August 2025", "paymentDate": "on or before 10th September 2025" }, { "type": "interim", "amountPerShare": 9, "recordDate": "February 15, 2025", "paymentDate": "February 28, 2025" } ], "ratings": { "CRISIL": { "long_term": 2, "short_term": 1 }, "India_Ratings": { "rating": "IND AA+", "outlook": "stable" } }, "merger": { "parties": [ "AOSPL", "AHIL" ], "effective_date": "April 1, 2024", "impact": "no impact on consolidated financial results (common control transaction)" }, "acquisitions": { "AOSPL": { "date": "August 7, 2024", "goodwill": 274000000, "purchasePrice": 274000000 }, "Searchlight_Health": { "date": "August 7, 2024", "dealValue": 675000000 } }, "auditType": "Consolidated Financial Results Review", "auditorName": "Deloitte Haskins & Sells LLP", "auditorOpinion": "no modified opinion", "materialityAssessment": "materiality considered both quantitative and qualitative", "goingConcernEvaluation": "no material uncertainty exists", "unauditedSubsidiaries": { "count": 1, "financials": { "totalAssets": 530000, "revenue": 0, "netLoss": 180000, "comprehensiveLoss": 850000, "netCashFlows": 0 }, "materialityAssessment": "not material" }, "associatesAndJointVentures": { "un auditedByAuditorCount": 6, "financials": { "netProfitQuarter": 106000000, "netProfitYear": 330000000, "comprehensiveProfit": 330000000 } }, "appointments":